BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28579855)

  • 1. Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.
    Caldeira D; Rodrigues FB; Pinto FJ; Ferreira JJ; Costa J
    Clin Med Insights Blood Disord; 2017; 10():1179545X17704660. PubMed ID: 28579855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Arthroscopic Surgery and Anterior Cruciate Ligament Reconstruction: A Meta-analysis of Randomized Controlled Trials.
    Zhu J; Jiang H; Marshall B; Li J; Tang X
    Am J Sports Med; 2019 Jul; 47(8):1994-2002. PubMed ID: 30113231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboprophylaxis for orthopedic surgery; An updated meta-analysis.
    Haykal T; Adam S; Bala A; Zayed Y; Deliwala S; Kerbage J; Ponnapalli A; Malladi S; Samji V; Ortel TL
    Thromb Res; 2021 Mar; 199():43-53. PubMed ID: 33422802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.
    Zhou H; Chen TT; Ye LL; Ma JJ; Zhang JH
    World J Surg Oncol; 2024 Feb; 22(1):69. PubMed ID: 38403630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis.
    Baloch MF; Adepoju AV; Falki V; Hajjaj M; Habet T; Habet K; Mahrosh A; Kundu S; Kataria J; Mathew M; Saka T; Al-Tawil M
    Cureus; 2023 Aug; 15(8):e43447. PubMed ID: 37711939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis.
    Almajdi A; Almutairi S; Alharbi M
    Thromb Res; 2023 Sep; 229():77-85. PubMed ID: 37419006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients: a systematic review and network meta-analysis.
    Xin Z; Liu F; Du Y; Mao F; Wang X; Xu P; Li Z; Qian J; Yao J
    Ann Palliat Med; 2020 Sep; 9(5):2970-2981. PubMed ID: 32787358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis.
    Zhou H; Ye LL; Zhou JT; Ma FX; Ma JJ; Zhang JH
    Surg Endosc; 2024 Mar; 38(3):1131-1138. PubMed ID: 38267639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
    Bhalla V; Abdel-Latif A; Bhalla M; Ziada K; Williams MV; Smyth SS
    Am J Cardiol; 2018 Oct; 122(7):1236-1243. PubMed ID: 30082040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA; Kahale L; Sperati F; Neumann I; Labedi N; Terrenato I; Barba M; Sempos EV; Muti P; Cook D; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD009447. PubMed ID: 24966161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.